MENU

Patient Commitment

Astellas Oncology is reimagining the patient
treatment experience

Our Patient Centricity Team combines behavioral science, novel insights, research, and partnerships to bring
real-world perspectives of patients into our process.

To learn more about our Patient Partnership Team, and to read about some of the projects and initiatives
we have delivered with patients, for patients, and hear what patient organization representatives say about
working with us, download our Annual Report. Anualreportarrow

We put patients first, working to better understand their needs. Our access support, C³ Prize, and
commitment to diverse clinical trials are just the beginning of our promise to change the course of cancer
treatment together.


Providing support for your patients

Astellas Pharma Support Solutions is designed to provide a single point of contact
to help patients overcome challenges accessing Astellas products.

See the enrollment forms below to get started:

PADCEV Support Solutions enrollment form
XOSPATA Support Solutions enrollment form
XTANDI Support Solutions enrollment form

For more detailed information such as help with authorization forms, denial appeal letters, and more,
visit the Astellas Pharma Support website Anualreportarrow

Fueling meaningful change
with the C³ Prize

Cancer is complex. Astellas Oncology recognizes the complexities of the cancer journey – in addition to medicine, people with cancer need comprehensive care.

At Astellas, we believe that having a conscious awareness of the patient in all activities, from every area of the company every single day, ensures we make the greatest impact possible on patients throughout their healthcare journey.

That’s why we are committed to fueling big ideas that tackle everyday challenges in cancer care beyond medicine. The C³ (Changing Cancer Care) Prize awards grants and resources to advance ideas that make a big impact in the cancer community. The C³ Prize directly reflects the mission of Astellas Oncology: to make every day better for those impacted by cancer.

Learn more about recent
C³ Grand Prize Winners
2022 Grand Prize Winner
Aimee DeGolyer

Idea:
A mobile app to help cancer patients track their own symptom data, enabling them to have greater control in their treatment. The app aims to reduce clinical team burden, drive deeper understanding of the patient's daily data and improve outcomes.

2020 Grand Prize Winner
Omolola Salako
Oncopadi.

Idea:
An app that connects cancer patients with the specialists and hospitals they need
to access care.

2019 Grand Prize Winner
Audrey Guth

Idea:
Expand the reach and impact of Nanny Angel Network, which delivers free,
specialized childcare for mothers with cancer.

Learn more about recent
C³ Grand Prize Winners
2022 Grand Prize Winner
Aimee DeGolyer

Idea:
A mobile app to help cancer patients track their own symptom data, enabling them to
have greater control in their treatment. The app aims to reduce clinical team burden,
drive deeper understanding of the patient's daily data and improve outcomes.

2020 Grand Prize Winner
Omolola Salako
Oncopadi.

Idea:
An app that connects cancer patients with the specialists and hospitals they need to access care.

2019 Grand Prize Winner
Audrey Guth

Idea:
Expand the reach and impact of Nanny Angel Network, which delivers free, specialized childcare for mothers with cancer.

Improving diversity in clinical trials

Improving diversity in
clinical trials

Astellas Oncology is committed to bringing underrepresented communities and demographics into more clinical trials.
A 2020 FDA review found that clinical trial participants' demographics differed significantly from the general U.S. population -- resulting in drugs being understudied in marginalized demographics.

Percent Participation in Clinical Trial by Subpopulation* for New Molecular Entities and Therapeutic Biologics Approved in 2020

White Black or
African American
Hispanic Asian
75% 8% 11% 6%

*The percentage of all other races combined (American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, Other, Unknown/Unreported) makes up to 100% of race category.

*The percentage of Non-Hispanic and Unknown/Unreported ethnicity makes up to 100% of ethnicity category.

*The percentage of patients from anywhere else in the world makes up to 100% of geographic category.

Gov W. SNAPSHOTS SUMMARY REPORT DRUG TRIALS.; 2021.
https://www.fda.gov/media/145718/download


Population Distribution by Race/Ethnicity: 2021

White Black or
African American
Hispanic Asian American Indian/
Alaska
Native
Native Hawaiian/
Other
Pacific
Islander
Multiple Races
58.2% 11.6% 19.0% 5.7% 0.5% 0.2% 4.9%
Hear from the experts about enhancing
clinical trials through diversity
Transforming innovative science into value for patients is our approach to finding solutions for cancer’s complexities.
See the innovation with our pipeline of products
and the partnerships that make it possible.